Published On: Mon, May 3rd, 2021

Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients

Tagged with: | | | | | | | |

has secured emergency use approval for from ’s Central Standard Control Organization () for the of Covid-19.

The Indian pharma company has been given the nod for Lilly’s oral JAK1/JAK2 inhibitor in 1mg, 2mg and 4mg strengths in combination with Remdesivir.

Natco Pharma said that it will be seeking a compulsory license based on emergency use and on the basis of grim public health emergency across India because of the second wave of the coronavirus pandemic.

Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients

Natco Pharma gets CDSCO nod for use of Baricitinib in Covid . Image courtesy of Daniel Roberts from Pixabay.

The Hyderabad-based pharma company is ready to release the product this week, in order to make it available to patients suffering from Covid-19 across India.

Related posts

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Recent Posts